
Profound Medical Corp. PROF
$ 7.66
3.51%
Annual report 2023
added 12-27-2025
Profound Medical Corp. Deferred Revenue 2011-2026 | PROF
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Profound Medical Corp.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 358 K | 655 K | 313 K | 241 K | 193 K | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 655 K | 193 K | 352 K |
Deferred Revenue of other stocks in the Medical devices industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acutus Medical
AFIB
|
401 K | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
563 K | - | 3.58 % | $ 2.21 M | ||
|
Alphatec Holdings
ATEC
|
10.4 M | $ 14.07 | 0.21 % | $ 2.11 B | ||
|
Cognyte Software Ltd.
CGNT
|
127 M | $ 6.86 | 3.63 % | $ 493 M | ||
|
ClearPoint Neuro
CLPT
|
2.12 M | $ 13.12 | -13.44 % | $ 355 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
508 K | - | - | $ 1.77 B | ||
|
Apollo Endosurgery
APEN
|
88 K | - | - | $ 475 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
424 K | - | -5.86 % | $ 30.6 M | ||
|
AxoGen
AXGN
|
14 K | $ 31.16 | -0.21 % | $ 1.43 B | ||
|
EDAP TMS S.A.
EDAP
|
6.64 M | $ 4.49 | -2.18 % | $ 167 M | ||
|
Aziyo Biologics
AZYO
|
533 K | - | 1.37 % | $ 20.5 M | ||
|
Apyx Medical Corporation
APYX
|
500 K | $ 3.4 | -0.58 % | $ 118 M | ||
|
Conformis
CFMS
|
215 K | - | - | $ 16.4 M | ||
|
Bio-Rad Laboratories
BIO
|
47.8 M | $ 269.99 | 0.13 % | $ 7.62 B | ||
|
BIOLASE
BIOL
|
2.45 M | - | -13.19 % | $ 166 K | ||
|
Bruker Corporation
BRKR
|
438 M | $ 40.1 | 0.53 % | $ 5.98 K | ||
|
BioSig Technologies
BSGM
|
16 K | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
313 M | $ 74.86 | 1.87 % | $ 111 B | ||
|
InMode Ltd.
INMD
|
11.9 M | $ 14.01 | 0.32 % | $ 906 M | ||
|
CryoLife, Inc.
CRY
|
1.45 M | - | -4.14 % | $ 702 M | ||
|
IRadimed Corporation
IRMD
|
2.26 M | $ 101.93 | 1.42 % | $ 1.29 B | ||
|
Cardiovascular Systems
CSII
|
2.11 M | - | 0.15 % | $ 844 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
33 | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
732 K | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
13.3 K | - | - | $ 462 M | ||
|
LivaNova PLC
LIVN
|
11.5 M | $ 70.52 | 0.33 % | $ 3.85 B | ||
|
Cutera
CUTR
|
10.4 M | - | -10.19 % | $ 1.99 M | ||
|
Medtronic PLC
MDT
|
315 M | $ 96.9 | 0.25 % | $ 125 B | ||
|
Delcath Systems
DCTH
|
170 K | $ 9.12 | -10.68 % | $ 260 M | ||
|
Intersect ENT, Inc.
XENT
|
137 K | - | - | $ 955 M | ||
|
Dynatronics Corporation
DYNT
|
150 K | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
621 K | - | - | $ 10.2 M | ||
|
Nano-X Imaging Ltd.
NNOX
|
140 K | $ 2.44 | -0.41 % | $ 143 M | ||
|
Second Sight Medical Products
EYES
|
335 K | - | -0.97 % | $ 54.4 M | ||
|
Establishment Labs Holdings
ESTA
|
1.75 M | $ 75.24 | -3.9 % | $ 2.12 B | ||
|
Insulet Corporation
PODD
|
14 M | $ 251.19 | 1.24 % | $ 17.7 B | ||
|
Quanterix Corporation
QTRX
|
9.47 M | $ 6.11 | -2.86 % | $ 230 M | ||
|
FONAR Corporation
FONR
|
4.29 M | $ 18.55 | -0.19 % | $ 122 M | ||
|
Sintx Technologies
SINT
|
4.72 K | $ 2.9 | -1.36 % | $ 10.8 M | ||
|
Globus Medical
GMED
|
27.7 M | $ 95.66 | -0.58 % | $ 12.9 B |